Purpose: To summarise the practical aspects of the development of techniques of interstitial permanent prostate brachytherapy (PPB) implantation. Prostate brachytherapy dates back to Pasteau's publication in 1913 describing the insertion of a radium capsule into the prostatic urethra to treat carcinoma of the prostate. Various implantation methods were employed but with unsatisfactory results until the development of the transrectal ultrasound in the 1980s. The subsequent two-stage Seattle technique allowed for a planned homogenous distribution of radioactive sources throughout the gland resulting in biochemical control comparable to surgical and external beam radiotherapy series. With the advent of advanced computer software and improved imaging, the technique has developed accordingly to a single stage procedure with ontable dosimetric assessment. The principles of targeting dose to the prostate while avoiding surrounding organs at risk remain as relevant today as nearly a century ago. There is an array of techniques to consider for the novice PPB provider. Whether the evolution of PPB techniques will translate into improved biochemical control is yet to be seen.
Introduction
Brachytherapy is radiation therapy in which radioactive sources are implanted directly into or in close proximity to a tumour. 1 In the context of localised prostate cancer, permanent prostate brachytherapy (PPB) is now an established procedure alongside external beam radiotherapy and radical prostatectomy as a valid curative modality, with recent follow-up data showing equivalent results. [2] [3] [4] It is interesting to note, however, that prostate brachytherapy actually outdates the retropubic radical prostatectomy by several decades. Hugh Young, 5 while mostly remembered for the development of the radical perineal prostatectomy at the very beginning of the twentieth century, carried out far more radiation therapy for prostate cancer than surgery. 6 Since then, a variety of techniques have been used to deliver radiation sources to the prostate. These have been driven by the quest to deliver a tumouricidal dose to the cancer-bearing prostate while sparing dose to the normal tissues to minimise urinary and rectal morbidity. Retropubic implantation of the prostate was the technique of choice over a decade ago but has been superseded by percutaneous transperineal implantation. With the aid of modern technical innovations, template guidance, computerised three-dimensional image-based planning and dosimetric analysis, the problems of seed distribution and dose homogeneity within the prostate have been overcome. This has led to an increase in tumour control and a decrease in toxicity.
The early years
Hugh Young and Benjamin Barringer pioneered early prostate brachytherapy following Pasteau's report of the insertion of a radium capsule into the prostatic urethra in Paris in 1913. [7] [8] [9] The original technique of irradiating the prostate from the urethra failed to treat the periphery of the gland and caused severe morbidity to the urethra. Young 9 tried to overcome this by applying doses of radium alternating in the urethra, bladder, rectum and from an external source, therefore maximising prostate dose with minimal dose (and side effects) to surrounding structures. These principles of radiotherapy remain today.
Barringer, 8 a urologist at New York's Memorial Hospital in 1917, had access to radon captured into gold needles, which he implanted into the prostate via the perineum. The needles were guided with a finger in the rectum allowing temporary interstitial implantation.
Dosage tables were soon developed including those from Paterson and Parker in Manchester. 10 The principles of the Paterson-Parker system were to plan and deliver a uniform dose of radiation (710% of the prescribed dose) with a nonuniform distribution of sources.
Early results were promising 9 and brachytherapy became a popular treatment for prostate cancer across North America in the prewar era. 6 However, perhaps owing to too many practitioners with little experience, long-term results were poor 6 and even in the best hands, superiority of the treatment over open prostatectomy was dubious 11 with cancer control achieved only with high doses causing intolerable morbidity. 12 Soon after the second World War, Flocks and his group in Iowa began interstitial radiation with radioactive gold in solution (colloidal gold). 13 This isotope has the theoretical advantage of providing localised intensive radiation thus avoiding toxicity to surrounding tissues: it was delivered by injection through an open suprapubic transvesical approach. Unfortunately, dose delivery was inhomogeneous throughout the prostate gland leaving underdosed areas ('cold-spots') in contrast to the increasingly popular external beam radiation. 13 Again at the Memorial Hospital, in the early 1970s, Whitmore et al.
14 developed the technique of open retropubic implantation of Iodine seeds administered through needles and guided by a digit in the rectum ( Figure 1 ). The dose and number of seeds required was calculated by estimating the size of the prostate at operation with use of a nomogram and then spacing the implantation needles appropriately. 15 Similarly Carlton et al. 16 were implanting radioactive gold seeds in Texas. Despite good early data, the long-term results of the retropubic era were unsatisfactory. This was largely attributed to technical difficulties such as visualisation and depth perception leading to poor distribution of the isotope within the gland.
17,18
The Seattle technique Permanent prostate brachytherapy was revolutionalised by the development of the transrectal ultrasound probe by Professor Holm in Denmark in the early 1980s. 19 This developed as a two stage procedure each requiring a separate admission and anaesthetic. Stage one consists of taking transverse ultrasound images of the prostate gland at 5 mm intervals from base to apex with the patient in the extended lithotomy position. The physicist and radiotherapist analyse the scans and produce a three-dimensional plan of seed distribution. At a later date (stage two) the patient is readmitted for the actual implant. Under anaesthesia the patient and prostate are positioned as close to the planning position as possible. The prostate is visualised by TRUS connected to a fixed stepping unit. Attached to the stepping unit is a brachytherapy template grid containing channels that run parallel to the probe. The preplan determines the position and distribution of preloaded needles containing the radioactive seeds and spacers. These needles are passed, under ultrasound guidance into the prostate through the perineum. When the tip of the needle is considered to be in the correct position (as determined by ultrasound visualisation) the seeds are deposited and the needle withdrawn. The major advantages of this technique over the open retropubic method are that ultrasound guidance allows far more precise dose distribution and avoids an open surgical procedure. The resulting dose distribution was crudely analysed from plain film radiographs. 19 Between 1984 and 1986, Dr Ragde visited the centre in Copenhagen and took the technique back to the Northwest Hospital in Seattle where it was developed further with Dr Blasko, Dr Grimm and others. 20 Early transrectal ultrasound allowed for transverse scanning only. Accurate implantation required recognition of the base plane and incremental retraction from this for effective dose distribution. The ultrasound system was further refined with the ability of multiplane scanning allowing a continuous longitudinal view and making depth perception technically easier. 20, 21 This meant that cranial-caudal movements of the prostate such as those that occur when a needle is inserted, could potentially be accounted for within the operating room. 22 With refinements in computer software and radiophysics, the technique has become known as the 'Seattle technique'. Variations on it include using CT or MRI for the preplan and/or the actual implant, performing the procedure under local anaesthetic 23 and the use of stabilising needles in order to minimise prostate movement. 24 Aerosolised jelly or a Foley catheter is used to optimise the ultrasonic urethral view. The Seattle technique generally requires two anaesthetics and separate visits: one for the planning and then later for implant. Where as the preplan scan can be carried out quickly and as an outpatient, on the second visit the prostate position must be identically replicated. It is well documented that the prostate is very mobile and changes shape, position and volume because of hormonal treatment, positioning, intraoperative oedema and rectal and bladder filling. [25] [26] [27] [28] Larger prostates can be technically difficult to implant owing to pubic arch interference: a prior assessment of this will identify those patients in advance giving the opportunity for hormonal manipulation in order to downsize the prostate but with associated morbidity. Despite efforts such as rectal preparation, bladder draining, and stabilising needles, difficulties in replicating the planning position as well as pubic arch interference 29 have led to deviations from the preplan.
27,30 Richard Stock and Nelson Stone at Mt Sinai, New York, addressed these issues by modifying the technique to a single stage inverse planning procedure.
31,32
From preplan to inverse plan: a single stage technique
The early Stock and Stone technique requires the patient to be placed in an extended dorsolithotomy position and under general or spinal anaesthetic, the transrectal ultrasound probe is inserted. This is stabilised by being fixed to the table or floor and has an attached perineal template with the same grid of channels to facilitate needle placement. The grid is replicated on the ultrasound monitor and the patient's position is optimised so that the prostate lies within the grid system aligned along the referenced baseline. Ultrasound measurements estimate the volume of the gland and from this a nomogram provides the amount of radioactivity required to treat the gland.
While imaging the widest part of the gland in the transverse plane, needles are inserted via the grid spaced approximately 1 cm apart with originally 60-70% of the needles in the periphery and now 75% in the periphery. 33, 34 If bony interference occurs then the patient can be repositioned accordingly. Seeds are then deposited in an 'afterloaded manner' along the length of the gland from base to apex and real-time fluoroscopy used to assess distribution. If an area appears deficient then further seeds can be added. The implant quality is audited with postimplant dosimetry at 1 month using CT imaging. In experienced hands dosimetry results have been good. 35 Stock and Stone were the first to demonstrate that the D90 (the dose delivered to 90% of the prostate volume as outlined using postimplant CT images) was associated with better outcomes. 36 Matzkin et al. 37 in Tel Aviv switched to this technique after treating 142 patients in the Seattle manner. They found that the subsequent 214 patients required less seeds, and had vastly improved dosimetric results with a mean D90 increase from an alarming 53% of the prescribed dose in the Seattle technique cohort to an acceptable 114%.
Computerised intraoperative planning
With developments in computer software, computerised planning has become faster and more efficient making intraoperative planning a practical reality: this dispenses with both a separate preplan procedure and the use of a nomogram along with their inherent disadvantages. 38 Wilkinson et al. 39 found a significant improvement in dose coverage of the prostate when comparing an intraoperative preplan approach with the traditional method of planning 2-4 weeks beforehand. 26 , 39 Gewanter et al. 38 showed that planning in the operating room added thirty minutes to the procedure but presented a favourable cost profile when the omission of a separate preplan procedure was taken into account.
Messing et al. 26 report on software known as PIPER (Prostate Implant Planning Engine for Radiotherapy). The program generates a plan intraoperatively after ultrasound image capture and operator delineation of the gland (stabilised with three needles). At the end of the procedure fluoroscopic radiographs are used to analyse seed placement as compared to the plan: any cold areas are compensated for by the addition of extra seeds. They found that only 18.2 min was added to operating time and dosimetric evaluation was equivalent to the preplan method. Kaplan et al. 30 also found equivalent dosimetric results, as did Beyer's group who had a total surgical time of less than 1 h. 40 Simply putting needles into the prostate gland causes changes in position, size and shape. 33, 41 With this in mind modern techniques plan after needles have been placed. Zelefsky et al. 42 describe the use of an in-house planning system at Memorial Sloan Kettering Cancer Center. After needles have been inserted in the prostate both peripherally and centrally, the prostate is outlined and the inverse plan is generated. A three-arm study comparing this three-dimensional optimisation technique with Stock's nomogram technique and the Seattle technique found better dosimetry and improved urethral morbidity with the first despite experience at the last. 42 The planning part of the three-dimensional optimisation technique took less than 20 min. 43 Cormack et al. 44 used interventional magnetic resonance imaging to provide real-time dosimetric feedback and updated the plan intraoperatively as appropriate. They found that 14 of 15 patients required alteration of the plan in order to achieve an acceptable implant.
Intraoperative dynamic dose-feedback
The above techniques, known as interactive planning, base intraoperative dosimetry on needle rather than seed location. 43, 45 Advanced dynamic dose calculation involves capturing seed position in real-time and continually updating the dosimetry taking into account any intraoperative deviation from the plan owing to prostate movement or technical seed misplacement. Deviations can then be corrected in real-time before the end of the procedure. 45, 46 This is the basis for the dynamic dosefeedback technique as advocated by Potters et al. 47, 48 Potters inserts needles approximately 1 cm apart under transrectal ultrasound guidance with a peripheral: central ratio of 3:1. Simultaneously, the dosimetrist registers the needle positions on Varian software. The Permanent prostate brachytherapy PL Acher et al next stage consists of outlining the prostate, urethra (visualised by aerosolised jelly) and rectum at 5 mm transverse ultrasound slices on the planning computer. The software then makes a plan by testing permutations of seed numbers and positions within the needles and constrained by preset rules based on maximum and minimum radiation doses to the prostate, urethra and rectum, aiming to use as little overall radiation as possible. Once a satisfactory plan is reached (within 45-60 s) and approved by the physician, seeds are afterloaded into the prostate accordingly. As each seed is placed, its position is visualised in real-time on sagittal view ultrasound and registered by the dosimetrist on to the software, which then immediately updates the dosimetry. Thus, the dosimetric evaluation is continually updated as the implant progresses. If dosimetric values are unsatisfactory at any point, then a new plan can be generated based on the already fixed seed positions. Postimplant dosimetry values based on CT scans at 3 weeks correlate well with the final intraoperative dosimetry (Figure 2 ). 47 The future Current American Brachytherapy Society guidelines define the quality of implants based on dosimetry values at 1 month on CT scan. 45 This dosimetric assessment gives valuable feedback to the operator team and provides a quality assurance. Several groups have found that intraoperative dosimetry correlates well with subsequent postoperative analysis 34, 47, 49 suggesting that satisfactory intraoperative dosimetry is a valid end point that may negate the need for routine postimplant analysis in the future.
Further improvements will inevitably occur in terms of imaging the prostate and seeds both intraoperatively and for postoperative dosimetric evaluation. These will involve not only new imaging technologies, but also more detectable material in the source capsule. These developments will help refine techniques as well as provide long-term feedback in terms of cancer control and morbidity. Mathematico-clinical models and improved understanding will help achieve the goals of predicting and accounting for intra-and postoperative oedema. 49 The ultimate aims of prostate brachytherapy, and indeed all curative modalities of prostate cancer, remain the same today as almost a century ago that is to treat the prostate cancer but cause as little harm as possible. 9 We now understand that increasing radiation dose beyond a certain threshold leads to negligible benefit. 36, 50, 51 With the use of modern imaging systems and computerised planning software we have now reached an era in which real-time planning and dosimetry are feasible within the operating room: each implant can be analysed and improved before the patient reaches the recovery area. 47 The more traditional transperineal techniques inevitably have longer follow-up data with pioneering results in experienced hands: 51, 52 there is no reason for those comfortable with these methods to change providing results are satisfactory. Perceived advantages of modern approaches include a more targeted implant with immediate technical feedback and the flexibility in the procedure to optimise implants 'on the table' as well as the convenience of a single visit for the patient. It remains to be seen whether these will translate into shorter learning curves and satisfactory disease control in the long term (Table 1) .
Historical aspects of dosimetry
222 Rn, 198 Au and 192 Ir seeds have been used for permanent implants of the prostate in the past. The historical background pertinent to dosimetry today began with the use of 121 I seeds at the New York Memorial Hospital in the late 1960s. 53 The total apparent activity to be implanted was determined by a dimension averaging method, initially empirically and eventually facilitated by a nomogram. Using this method the minimum effective dose was believed to be about 160 Gy. Quimby and Manchester volume implant data were used for early evaluation of this dimension averaging method. 54, 55 To provide feedback to the brachytherapy clinicians, Memorial Hospital dosimetrists reported the dose for which the isodose contour volume was the same as the target volume measured at surgery which became known as the matched peripheral dose (MPD). 56 The target was usually approximated as an ellipsoid, for which the volume is the product of the three dimensions multiplied by p/6. With the advent of CT planning the minimum peripheral dose received by 57 Comparisons with the old dosimetry methods show that a 53 cc volume receiving 160 Gy would receive 144 Gy calculated with the TG43 dosimetry data. 58 It is now recommended that the pre-TG43 prescribed dose of 160 Gy becomes 145 Gy. 57 
